University of Houston College of Pharmacy
4849 Calhoun, Room 4035
Houston, TX 77204-5039
PGY-1 Pharmacy Practice Residency, Louisiana State University Health Sciences Center, Shreveport, LA
Doctor of Pharmacy, Auburn University Harrison School of Pharmacy, Auburn, AL
B.S. in Biomedical Sciences, Auburn University, Auburn, AL
- Antifungal PK/PD and mechanisms of resistance
- Host immune response to Candida spp.
- Rapid diagnostics for bloodstream infections
Wurster S, Bandi A, Beyda ND, Albert ND, Raman NM, Raad II, Kontoyiannis DP. Drosophila melanogaster as a model to study virulence and azole treatment of the emerging pathogen Candida auris. J Antimicrob Chemother. 2019 Jul 1;74(7):1904-1910.
Dilworth TJ, Casapao AM, Ibrahim OM, Jacobs DM, Bowers DR, Beyda ND, Mercier RC. Adjuvant β-Lactam Therapy Combined with Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: Does β-Lactam Class Matter? Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02211-18. doi: 10.1128/AAC.02211-18. Print 2019 Mar.
Beyda ND, Amadio J, Rodriguez JR, Malinowski K, Garey KW, Wanger A, Ostrosky-Zeichner L. In Vitro Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals. J Clin Microbiol. 2018 Jul 26;56(8). pii: e00471-18. doi: 10.1128/JCM.00471-18. Print 2018 Aug.
Sofjan AK, Musgrove RJ, Beyda ND, Russo HP, Lasco TM, Yau R, Restrepo A, Garey KW. Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary centre in the USA. J Glob Antimicrob Resist. 2018 Dec;15:41-47.
Sofjan AK, Mitchell A, Shah DN, Nguyen T, Sim M, Trojcak A, Beyda ND, Garey KW. Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist. 2018 Sep;14:58-64.
Jacobs DM, Dilworth TJ, Beyda ND, Casapao AM, Bowers DR. Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: a Multi-institutional Study. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01464-17. doi: 10.1128/AAC.01464-17. Print 2018 Jan.
Casapao AM, Jacobs DM, Bowers DR, Beyda ND, Dilworth TJ. Early Administration of Adjuvant ß-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis. REACH-ID Study Group. Pharmacotherapy. 2017 Nov;37(11):1347-1356.
Beyda ND, Liao G, Endres BT, Lewis RE, Garey KW. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata. Antimicrobial Agents and Chemotherapy 2015 Sep;59(9):5405-12
Garey KW, Aitken SL, Dima-Ala A, Beyda ND, Kuper K, Xie Y, Koo HL. Echinocandin use in hospitalized patients: A multi-institutional study. American Journal of Medical Sciences 2015; 349(4):316-20.
Jacobs DM, Beyda ND, Asuphon O, Jahangir Alam M, Garey KW. Host factors and clinical outcomes of Candida colonization in critically ill patients. Mycopathologia 2015; 179(1-2):87-93.
Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW. FKS mutant Candida glabrata; risk factors and outcomes in patients with candidemia. Clinical Infectious Diseases 2014; 58(6):819-25.
Aitken SL, Beyda ND, Shah DN, Palmer HR, Lasco TM, Koo H, Garey KW. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Annals of Pharmacotherapy 2014; 48(6):683-90.
Beyda ND, Alam MJ, Garey KW. Comparison of the T2DX instrument with T2Candida Assay and automated blood culture in the detection of Candida species using simulated blood cultures. Diagn Microbiol Infect Dis. 2013 Dec;77(4):324-6.
Beyda ND, Regen S, Lewis RE, Garey KW. Immunomodulatory agents as adjunctive therapy for the treatment of resistant Candida species. Curr Fungal Infect Rep (2013) 7: 119.
Jardin CG, Palmer HR, Shah DN, Le F, Beyda ND, Jiang ZD, Garey KW. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. J Hosp Infect. 2013 Sep;85(1):28-32.
Beyda ND, Chuang SH, Alam MJ, Shah DN, Ng TM, McCaskey L, Garey KW. Treatment of Candida famata bloodstream infections: case series and review of the literature. Journal of Antimicrobial Chemotherapy 2013; 68(2):438-43
Beyda ND, Lewis RE, Garey KW. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Annals of Pharmacotherapy 2012; 46:1086-96
Tran TT, Beyda ND, Biehle LR, Cottreau JM, Echevarria K, Musick WL, Perez KK, Schilling AN; on Behalf of The Houston Infectious Diseases Network. Significant publications on infectious diseases pharmacotherapy 2011. American Journal of Health-System Pharmacy 2012; 69(19): 1671-1681
Eiland E, Beyda ND, Han J, Lindgren W, Ward R, English TM, Hassoun A, Hathcock K. The utility of rapid microbiological and molecular techniques in optimizing antimicrobial therapy. SRX Pharmacology 2010, Article ID 395215
Beyda ND, Cluck D, Taba KE, Middlebrooks M. Ocular manifestations of systemic diseases. US Pharmacist April 2010; HS2-HS8
Beyda ND, Eiland E. Rapid molecular testing in bloodstream infections: improving patient outcomes, reducing health care costs, and aiding clinical pharmacists in decision making. US Pharmacist Sept 2009; HS9-13
Beyda ND, Amadio J, Rodriguez JR, Malinowski K, Garey KW, Wanger A, Ostrosky-Zeichner. Evaluation of BacT/Alert FA blood culture bottles and T2Candida assay for detection of Candida in the presence of antifungals. 1st ASM Microbe - June 17th - 20th, 2016 Boston, MA
Casapao AM, Jacobs DM, Bowers DR, Beyda ND, Dilworth TJ. Early beta-lactam (BL) therapy combined with standard therapy (STAN) for methicillin resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) compared to STAN alone: A multicenter, retrospective, propensity-matched analysis. 55th ICAAC - September 17th-21st, 2015 San Diego, CA
Endres BT, Liao G, Beyda ND. Mutation of FKS2 evokes significant changes in echinocandin mediated beta-glucan unmasking, chitin synthesis, and macrophage activation in Candida glabrata. 55th ICAAC - September 17th-21st, 2015 San Diego, CA
Beyda ND, Lewis RE, Liao GL, Garey KW. Innate inflammatory response and immuno-pharmacologic activity of antifungals against clinical bloodstream isolates of wild-type (WT) and FKS mutant Candida glabrata. 54th ICAAC - September 5-9, 2014 Washington DC
Beyda ND, Gschwind L, Shah DN, Nguyen A, Lasco TM, Garey KW. Risk factors and clinical significance of persistent candidemia in hospitalized patients. 54th ICAAC - September 5-9, 2014 Washington, DC
Beyda ND, John J, Alam MJ, Kilic A, Lasco TM, Garey KW. Echinocandin resistant Candida glabrata; Risk factors and outcomes in patients with candidemia. 53rd ICAAC, September 10-13, 2013, Denver, CO
Jacobs DM, Asuphon O, Beyda ND, Alam MJ, Garey KW. Host factors for Candida colonization in critically ill patients. 53rd ICAAC, September 10-13, 2013, Denver, CO
Aitken SL, Beyda ND, Shah DN, Palmer HR, Lasco TM, Koo H, Garey KW. Clinical practice patterns in hospitalized patients at risk for candidemia: Implications for rapid candida detection methods. 53rd ICAAC, September 10-13, 2013, Denver, CO
Beyda ND, Alam MJ, Garey KW. Comparison of the T2 Biosystems Candida assay and automated blood culture in the detection of Candida species using simulated blood cultures. 113th American Society for Microbiology General Meeting, May 18-21, 2013, Denver, CO
Beyda ND, Shah DN, Cottreau J, Salazar M, Frost C, Lasco TM, Garey KW. Aggregate measures of antifungal use in hospitalized patients: Defined daily doses vs. antimicrobial days. IDWeek 2012, October 17-21, 2012, San Diego, CA
Beyda ND, Kilic A, Alam MJ, Lasco TM, Garey KW. Molecular epidemiology and fluconazole susceptibility of Candida glabrata candidemia at a university-affiliated medical center. 52nd ICAAC, September 9-12, 2012, San Francisco, CA
Alimi AD, Shah DN, Beyda ND, Kilic A, Garey KW. Incidence of positive microbiological cultures in patients with Clostridium difficile infection (CDI). 46th American Society of Health System Pharmacists Midyear Clinical Meeting, December 4-8, 2011, New Orleans, LA
Morgan GH, Shah DN, Beyda ND, Mason C, Garey KW. Change in fluconazole susceptibilities based on application of revised Clinical Laboratory Standards Institute (CLSI) breakpoints. 46th American Society of Health System Pharmacists Midyear Clinical Meeting, December 4-8, 2011, New Orleans, LA
Jardin CG, Palmer HP, Le F, Beyda ND, Garey KW. Assessment of treatment patterns and patient outcomes pre-versus post-implementation of a severity based Clostridium difficile infection (CDI) treatment policy. 51st ICAAC, September 17-20, 2011, Chicago, IL
Beyda ND, Garey KW, Palmer H. Examination of Antifungal Exposure and Persistent Candidemia Isolate Susceptibility. ALCALDE XXV Southwest Leadership Conference, April 14-15, 2011, San Antonio, TX
Beyda ND, Cockerham M, Parish R, Trimble K. Fungal prophylaxis: Incidence of invasive fungal infections in acute myelogenous leukemia and myelodysplastic syndrome. ALCALDE XXIV Southwest Leadership Conference, April 8-9, 2010, Galveston, TX
Beyda ND, Cockerham M, Parish R, Trimble K. Posaconazole versus Fluconazole for Prophylaxis of Invasive Fungal Infections in Patients with Hematologic Malignancies. 44th American Society of Health System Pharmacists Midyear Clinical Meeting, Decemeber 6-10, 2009, Las Vegas, NV
Eiland EH, Beyda ND, Han J, Hassoun A, Lindgren W, Ward R, English TM, Hathcock K. Utility of Target Enriched Multiplex Polymerase Chain Reaction (Tem-PCR) by Clinical Pharmacists in Optimizing Antimicrobial Therapy in Patients with Staphylococcal Bloodstream Infections. Association for Molecular Pathology 2009 Annual Meeting, November 19-22, 2009, Kissimmee, FL
Handy Tools for Approaching Clinical Infectious Diseases Questions, Texas Society of Health Systems Pharmacists 2015 Annual Seminar, ACPE# 0156-0000-15-145-L01-P,April 2015
Preventing antifungal resistance: Host, pathogen, drug , Faculty Seminar Series,University of Houston College of Pharmacy,February 2014
Newly revised azole and echinocandin clinical breakpoints for Candida species Advisory board meeting: Center for Antimicrobial Stewardship and Epidemiology, Baylor-St. Luke's Medical Center,April 2013
Optimizing fluconazole and echinocandin pharmacokinetics and pharmacodynamics: Improving outcomes in mice then men, St. Luke’s Episcopal Hospital Seminar, May 2011
Overview of Antifungals, St. Luke’s Episcopal Hospital ID Morning Report, January 2011
Impact of rapid microbiological testing on patient outcomes, St. Luke’s Episcopal Hospital ID Morning Report, October 2010
Therapeutic drug monitoring of voriconazole and posaconazole: A review of supporting evidence Louisiana State University Health Sciences Center-Shreveport Seminar, May 2010
Fungal prophylaxis: Incidence of invasive fungal infections in acute myelogenous leukemia and myelodysplastic syndrome, ALCALDE Southwest Leadership Conference, April 2010
CE: Community Associated Methicillin Resistant Staphylococcus aureus, Louisiana Society of Health Systems Pharmacists 2009 Mid Year Meeting, ACPE# 179-000-09-037-L01-P/T, October 2009
- Young Investigator Research Award, "Uncovering novel mechanisms governing non-FKS mediated echinocandin resistance in C. glabrata," Society of Infectious Diseases Pharmacists, 2017
- “Top 10 Mycology Papers for 2015” – Beyda ND, et al. CID 2014; 58(6):819-25 55th International Conference on Antimicrobial Agents & Chemotherapy, 2015
- “Top 10 Mycology Papers for 2014” – Beyda ND, et al. CID 2014; 58(6):819-25 54th International Conference on Antimicrobial Agents & Chemotherapy, 2014
- Scholarship award supported by Howard Hughes Medical Institute and Burroughs Wellcome Fund to attend Woods Hole Molecular Mycology Course, 2013
- ICAAC Infectious Diseases Fellows Grant, American Society for Microbiology, 2012
- IDSA Travel Grant, Infectious Diseases Society of America, 2012
- Special Recognition Award: Excellence in Clinical Skills, University of Houston College of Pharmacy, 2008
- Golden Key International Honor Society, University of Houston, 2003-2005
- Tau Sigma Honor Society, 2003-2005
- American College of Clinical Pharmacy, 2009 – present
- American Society for Microbiology, 2009 – present
- The Society of Infectious Disease Pharmacists, 2009 – present
- Kappa Psi Pharmaceutical Fraternity, 2005 – present
- Ad Hoc Reviewer, Annals of Pharmacotherapy
- Ad Hoc Reviewer, Journal of Chemotherapy
- Ad Hoc Reviewer, Journal of Pharmacy Technology
- Ad Hoc Reviewer, Medical Mycology
- Ad Hoc Reviewer, Mycoses
- Ad Hoc Reviewer, US Pharmacist